2022
Cardiac Complications of Human Babesiosis
Spichler-Moffarah A, Ong E, O’Bryan J, Krause PJ. Cardiac Complications of Human Babesiosis. Clinical Infectious Diseases 2022, 76: e1385-e1391. PMID: 35983604, PMCID: PMC10169432, DOI: 10.1093/cid/ciac525.Peer-Reviewed Original ResearchConceptsYale-New Haven HospitalCardiac complicationsRisk factorsIntensive care unit stayCardiovascular disease risk factorsHuman babesiosisCommon cardiac complicationHigh-grade parasitemiaLife-threatening complicationsDisease risk factorsLonger median lengthQT interval prolongationHigh mortality rateUnit stayComplication groupTick-borne diseaseAdult patientsCardiac outcomesMost patientsThin blood smearsHeart failureInterval prolongationModerate illnessRecord reviewAtrial fibrillation
2007
ATOVAQUONE AND AZITHROMYCIN TREATMENT FOR BABESIOSIS IN AN INFANT
Raju M, Salazar JC, Leopold H, Krause PJ. ATOVAQUONE AND AZITHROMYCIN TREATMENT FOR BABESIOSIS IN AN INFANT. The Pediatric Infectious Disease Journal 2007, 26: 181-183. PMID: 17259886, DOI: 10.1097/01.inf.0000250622.11505.8f.Peer-Reviewed Original ResearchConceptsCyanotic heart diseaseBabesia microti infectionTreatment of childrenOral azithromycinThin blood smearsInitial presentationSevere anemiaHeart diseaseMicroti infectionPolymerase chain reactionHepatic enzymesBlood smearsInfantsIntraerythrocytic parasitesChain reactionTreatmentBabesiosisLaboratory testsFebrileThrombocytopeniaCyanoticAnemiaClindamycinSerologyAzithromycin